Global Chronic Hepatitis B (CHB) Market Size to Exceed USD 3883.66 Million by 2035 | CAGR of 3.50%

Global Chronic Hepatitis B (CHB) Market Size to Exceed USD 3883.66 Million by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Chronic Hepatitis B (CHB) Market Size is expected to Grow from USD 2,764.4 Million in 2024 to USD 3,883.66 Million by 2035, at a CAGR of 3.50% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Chronic Hepatitis B (CHB) Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Antivirals, and Immune Modulators), By Gender (Male, and Female), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035."   

Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/chronic-hepatitis-b-chb-market                

The chronic hepatitis B (CHB) market includes medications, immunotherapies, vaccines, and healthcare frameworks aimed at preventing, diagnosing, and treating HBV infections globally. HBV, the primary cause of serious liver illness, transmits through blood and infected fluids due to unprotected sexual activity, drug abuse, or the sharing of needles. Many acute infections typically clear up on their own within 1-2 months, but lasting longer than six months results in CHB, increasing the risk of cirrhosis, liver failure, or cancer. Symptoms encompass tiredness, queasiness, stomach discomfort, fever, yellowing of the skin and eyes, and sometimes skin rashes or joint aches, which are more frequent in adults compared to children. Moreover, increasing global CHB prevalence boosts the need for diagnostics, nucleoside analogues, and novel therapies that enhance viral management and results. The market encounters obstacles such as expensive treatment prices, limited curative alternatives, pharmaceutical difficulties, and minimal awareness, hindering access and execution.

The antivirals segment accounted for the largest share of the market in 2024 and is projected to grow at a significant CAGR over the forecast period.       

Based on the drug class, the chronic hepatitis B (CHB) market is segmented into antivirals, and immune modulators. Among these, the antivirals segment accounted for the largest share of the market in 2024 and is projected to grow at a significant CAGR over the forecast period. HBV DNA is effectively eliminated by antiviral therapy for chronic hepatitis B, and it is influenced by host genetics, positive and slower status, and adherence drives to which results in histological improvement and a lower risk of HCC.

The male segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on gender, the chronic hepatitis B (CHB) market is divided into male, and female. Among these, the male segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is because of higher baseline HBV DNA levels, androgen-enhanced viral replication, and host factors like genotype C infection or family history of which leads to high cases as compared to females.

Asia Pacific is expected to hold the majority share of the global chronic hepatitis B (CHB) market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global chronic hepatitis B (CHB) market during the forecast period. Asia Pacific dominates the CHB market due to fast-expanding healthcare systems, creative R&D, government funding, and high prevalence, which have strong public health programs. China accounts for around one-third of regional income through vaccination, screening, and antiviral reimbursements. India is the fastest-growing, with universal immunisation, affordable generics, and increased diagnostics access in underprivileged areas.

North America is anticipated to grow at the fastest pace in the global chronic hepatitis B (CHB) market during the forecast period. North America, dominated by the United States (850,000-2.2 million CHB infections per CDC), has a substantial CHB market share due to good screening, antiviral reimbursements (e.g., tenofovir), and advances from Gilead and Vir Biotechnology in a solid healthcare system.

Major vendors in the global chronic hepatitis B (CHB) market are Antios Therapeutics, Arbutus Biopharma, Ascletis Pharmaceuticals, Assembly Biosciences, Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen and Arrowhead Pharmaceuticals, Janssen Sciences Ireland, Roche, Romark Laboratories, Vedanta Biosciences, Vir Biotechnology, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In December 2025, SVF Vaccines, a portfolio business of Karolinska Development AB, revealed fresh preclinical findings on its hepatitis B and D-targeting vaccine SVF-001. Additionally, as a late-breaking abstract at the HepDart scientific conference in Honolulu, Hawaii, from December 7–11. An extended antiviral effect in preclinical models was demonstrated by the results, which were follow-up data from a previously published study.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the chronic hepatitis B (CHB) market based on the below-mentioned segments:  

Global Chronic Hepatitis B (CHB) Market, By Drug Class

• Antivirals
• Immune Modulators

Global Chronic Hepatitis B (CHB) Market, By Gender

• Male
• Female

Global Chronic Hepatitis B (CHB) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa